Introduction:
Leading pharmaceutical company has secured a new CDMO contract with UK/EU-based firms for 15 APIs. This expansion follows a prior agreement in February 2024, highlighting significant growth and future global partnerships in multiple regions.
Share price movement of Bajaj Healthcare:
On December 10, 2024, Bajaj Healthcare Ltd opened at ₹463.85, up 3.36% from its previous close of ₹448.75. The stock reached a high of ₹466.30 and a low of ₹446.35. By 10:20 AM, it traded at ₹466.30, a 3.93% increase, with a market cap of ₹1,232.82 crore.
Bajaj Healthcare expands CDMO partnerships:
Bajaj Healthcare Limited has entered into a new CDMO contract with UK/EU-based companies for 15 new APIs. This follows a previous contract signed in February 2024 for another 15 molecules, marking significant growth in its global partnerships.
The new CDMO pipeline includes both off-patent generic APIs and some under patent. This expansion highlights the company’s commitment to developing cost-effective synthesis routes and enhancing its manufacturing capabilities, particularly at its USFDA, EU, and TGA-approved site in Vadodara, Gujarat.
Mr. Anil Jain, Managing Director, expressed excitement about the company’s growing global presence, with plans for additional CDMO deals in Australia, New Zealand, and South Africa. The TGA approval is key to these expansions.
Recent news on Bajaj Healthcare:
As of November 16, 2024, Bajaj Healthcare reported a strong Q2 FY25 with a net profit of ₹94.64 crore, up from a loss last year. Revenue surged 31.5% YoY, driven by growth across multiple segments including opium processing and API exports.
Stock performance of Bajaj Healthcare for Period of 1 week, 6 months and 1 year:
Bajaj Healthcare Ltd has shown strong performance with a 15.3% return over the past week, 44.6% over the last six months, and 22.8% over the past year, reflecting solid growth and investor confidence in its prospects.
Also Read: Tata group stock jumps after Vodafone Idea selects the company for scaling up 4G and 5G rollouts
Shareholding pattern of Bajaj Healthcare:
| All values in % | Sep 2024 | Jun 2024 | Mar 2024 |
| Promoter | 59.20% | 67.70% | 67.70% |
| FII | 2.50% | 0.00% | 0.50% |
| DII | 2% | 0% | 0% |
| Public | 36.40% | 32.30% | 31.30% |
About Bajaj Healthcare:
Bajaj Healthcare Ltd (NSE: BAJAJHCARE) is a leading bulk drug manufacturer established in 1993. Headquartered in Thane, it operates multiple API and formulation plants across Gujarat and Maharashtra, catering to global pharmaceuticals, nutraceuticals, and food industries.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
